WallabyPhenox has today announced the successful completion of a significant funding round aimed at strengthening its financial foundation. The proceeds will be utilised to fully restructure the company’s capital framework and accelerate its long-term global growth initiatives, as per a WallabyPhenox press release.
The financing was led by Yunfeng Capital, HJ Partners, Gaorong Venture, Junsong Capital, and Qianhai Ark Asset Management, with participation from Enlight Medical.
Additionally, following this milestone, Enlight Medical and WallabyPhenox have merged to form a fully integrated neurovascular company with an enhanced global footprint.
The release goes on to note that this funding will help to optimise WallabyPhenox’s balance sheet, enhance operational flexibility, and support key strategic initiatives, including major clinical programmes and the continued expansion of its global product portfolio.
WallabyPhenox is currently preparing to initiate PIANO—a landmark US clinical trial designed to expand access to flow diversion therapy within one of the fastest-growing segments of the neurovascular market. The company anticipates enrolling its first patient imminently, the release adds.
In parallel, WallabyPhenox is launching the multicentre TRUST registry in Europe, which is designed to generate real-world evidence evaluating outcomes across multiple neurovascular treatment modalities.
This financing will enable the company to “remain true to its heritage of innovation, courage and disruption”, the release also states, highlighting the fact that WallabyPhenox brought the first 64-wire flow diverter to market in 2012 and became the first company to test its technology through randomised controlled trials, demonstrating the safety of minimising antiplatelet drug therapy via the COATING and DART studies.
WallabyPhenox claims that its presence across established technologies will be strengthened while the company simultaneously looks to expand its footprint into emerging innovation areas, including early-stage brain-computer interface (BCI) platforms.
“This financing marks a pivotal moment for WallabyPhenox,” said Ruilin Zhao, the company’s chief executive officer (CEO). “We are strengthening our financial foundation while accelerating our commitment to clinical excellence and global expansion. By combining established, proven neurovascular technologies with robust clinical initiatives, such as PIANO and TRUST, we are positioning ourselves to broaden patient access worldwide.”
